Our Ref: 76/2022

JANUARY 2022



Re: Your request made under the Freedom of Information Act 2000

Question 1.

How many patients were treated by your Trust in the last 3 months with the following drugs:

Adalimumab	Adalimumab	Adalimumab	Adalimumab	Adalimumab
(Amgevita)	(Humira)	(Hyrimoz)	(Idacio)	(Imraldi)
652	51	0	0	0

Question 2.

Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had **not** been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by:

New Humira patients – all departments	New Humira patients - rheumatology	New Humira patients – dermatology	New Humira patients – gastroenterology
1	1	0	0

Question 3.

Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department:

New Adalimumab	New Adalimumab	New Adalimumab	New Adalimumab
Biosimilar patients –	Biosimilar patients –	Biosimilar patients –	Biosimilar patients –
all departments	rheumatology	dermatology	gastroenterology
36	18	1	9

⁸ patients where specialty cannot be determined from pharmacy data